Amgen
Biotechnology · United States
Amgen discovers, makes and sells biotechnology medicines for bone health, cholesterol, inflammation, cancer and rare diseases, plus biosimilars, selling mostly through three large U.S. wholesalers.
What makes it different
Seventeen different medicines each sell over $1 billion a year.
17Products annualizing above $1BQ2 2026
Sales are spread across many drugs, so no single patent expiry decides its future.
How big it is
How big is Amgen?
$36.8BTotal revenuesFY2025
31,500StaffFY2025
50+CountriesFY2025
How it makes money FY2025
Spread across many medicines.
- Prolia12%$4.4B
- Repatha8%$3.0B
- Otezla6%$2.3B
- ENBREL6%$2.2B
- Other68%
How the business works
Discover biologics. Make them. Defend sales.
- 1Antibody and protein medicines
- 2Own biomanufacturing plants
- 3Through three U.S. wholesalers
Older blockbusters like Prolia and ENBREL now face biosimilars and price setting, so newer drugs must replace them.
Who owns it
- BlackRock, Inc.7.6%
- Vanguard Capital Management7.51%
- Capital World Investors5.5%
CEO: Robert A. Bradway
Who it competes with
Key moments
- 1980AMGen (Applied Molecular Genetics) is founded in Thousand Oaks
- 2012Robert A. Bradway becomes CEO
- 2019Completes acquisition of Otezla
- 2023Acquires Horizon Therapeutics, creating a Rare Disease business
- 2025MariTide obesity drug enters Phase 3
Sources
Every number on this page comes from Amgen's own reports.
Full profile
The rest of the story is in the app.
What Amgen tracks21 metrics
Phase 3 programs
Products annualizing above $1B
Staff members
Results, quarter by quarterwith a chart
Revenue
Profit
Margin
Where the money comes from2 regions
United States
Rest of world
The full timeline13 moments
2015
2016
2024
Amgen vs Novartisside by side
Revenue
Profit
People
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
